Bayer Aktiengesellschaft (BAYRY) is significantly outperforming the medical sector, with a year-to-date gain of 45.3% compared to the sector's average loss of 5.8%; this outperformance is supported by a 9.4% increase in the Zacks Consensus Estimate for full-year earnings over the past 90 days, resulting in a Zacks Rank of #2 (Buy). BioCryst Pharmaceuticals (BCRX) is another medical stock showing strong gains, up 43.5% year-to-date, with a 359.5% increase in consensus EPS estimates over the last three months, also earning a Zacks Rank #2 (Buy).
Bayer Aktiengesellschaft (BAYRY) has demonstrated significant outperformance within the Medical sector this year, achieving a year-to-date gain of approximately 45.3%, starkly contrasting with the Medical group's average loss of 5.8%. This strong performance is underpinned by improving analyst sentiment, as evidenced by a 9.4% increase in the Zacks Consensus Estimate for BAYRY's full-year earnings over the past 90 days, contributing to its Zacks Rank of #2 (Buy). Furthermore, BAYRY has also outperformed its specific Large Cap Pharmaceuticals industry, which has seen an average loss of 4.3% year-to-date. Similarly, BioCryst Pharmaceuticals (BCRX) has registered a substantial year-to-date gain of 43.5%, accompanied by a notable 359.5% increase in its consensus EPS estimate for the current year over the past three months, also securing a Zacks Rank #2 (Buy). While BCRX's industry, Medical - Drugs, has experienced a slight decline of 0.9% year-to-date, BCRX itself has shown robust growth. Both companies are highlighted due to their strong recent returns and positive revisions in earnings outlooks, suggesting favorable underlying fundamentals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
